85 related articles for article (PubMed ID: 19504558)
1. Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel.
Grau JJ; Caballero M; Campayo M; Jansa S; Vargas M; Alós L; Monzo M
Laryngoscope; 2009 Aug; 119(8):1484-90. PubMed ID: 19504558
[TBL] [Abstract][Full Text] [Related]
2. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
3. Serum vascular endothelial growth factor as a predictive factor in metronomic (weekly) Paclitaxel treatment for advanced head and neck cancer.
Caballero M; Grau JJ; Blanch JL; Domingo-Domenech J; Auge JM; Jimenez W; Bernal-Sprekelsen M
Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1143-8. PubMed ID: 18025320
[TBL] [Abstract][Full Text] [Related]
4. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
[TBL] [Abstract][Full Text] [Related]
5. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival.
Azad AK; Bairati I; Samson E; Cheng D; Mirshams M; Qiu X; Savas S; Waldron J; Wang C; Goldstein D; Xu W; Meyer F; Liu G
Clin Cancer Res; 2012 Jan; 18(1):196-206. PubMed ID: 22076708
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
7. Association study of the G-protein beta3 subunit C825T polymorphism with disease progression an overall survival in patients with head and neck squamous cell carcinoma.
Lehnerdt GF; Franz P; Bankfalvi A; Grehl S; Jahnke K; Lang S; Schmid KW; Siffert W; Frey UH
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3203-7. PubMed ID: 18990763
[TBL] [Abstract][Full Text] [Related]
8. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
9. A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder.
Sakano S; Kumar R; Larsson P; Onelöv E; Adolfsson J; Steineck G; Hemminki K
BJU Int; 2006 Apr; 97(4):847-51. PubMed ID: 16536785
[TBL] [Abstract][Full Text] [Related]
10. MDR1 diplotypes as prognostic markers in multiple myeloma.
Maggini V; Buda G; Martino A; Presciuttini S; Galimberti S; Orciuolo E; Barale R; Petrini M; Rossi AM
Pharmacogenet Genomics; 2008 May; 18(5):383-9. PubMed ID: 18408561
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome.
Woo DK; Jones CR; Vanoli-Storz MN; Kohler S; Reddy S; Advani R; Hoppe RT; Kim YH
Arch Dermatol; 2009 Jun; 145(6):667-74. PubMed ID: 19528422
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
13. Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma.
Okuwaki Y; Nakazawa T; Kokubu S; Hidaka H; Tanaka Y; Takada J; Watanabe M; Shibuya A; Minamino T; Saigenji K
Am J Gastroenterol; 2009 Nov; 104(11):2747-53. PubMed ID: 19603009
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
Cao W; Xu C; Lou G; Jiang J; Zhao S; Geng M; Xi W; Li H; Jin Y
Jpn J Clin Oncol; 2009 Sep; 39(9):582-7. PubMed ID: 19509000
[TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial.
Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T;
Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061
[TBL] [Abstract][Full Text] [Related]
16. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
Hoskin PJ; Robinson M; Slevin N; Morgan D; Harrington K; Gaffney C
J Clin Oncol; 2009 Dec; 27(34):5751-6. PubMed ID: 19884550
[TBL] [Abstract][Full Text] [Related]
17. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
18. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.
Naoki K; Kunikane H; Fujii T; Tsujimura S; Hida N; Okamoto H; Watanabe K
Jpn J Clin Oncol; 2009 Sep; 39(9):569-75. PubMed ID: 19520687
[TBL] [Abstract][Full Text] [Related]
19. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]